Literature DB >> 25939027

The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia.

Peter J Weiden1, Rebecca S Roma, Dawn I Velligan, Larry Alphs, Matthew DiChiara, Brad Davidson.   

Abstract

OBJECTIVE: To characterize patterns of communication in the offer of long-acting injectable (LAI) antipsychotic medication made by psychiatrists to patients with schizophrenia by (1) examining the style and content of their interaction and (2) determining how these may have driven the ultimate response to recommendations for LAI therapy.
METHOD: This was an observational study conducted at 10 community mental health centers in 3 waves from July 2010 to May 2011. The final dataset for discourse analysis was 33 recorded conversations in which a psychiatrist offered an injectable antipsychotic to a patient with schizophrenia. These visits were transcribed and analyzed by a team of linguists and social scientists.
RESULTS: Our primary finding is that, based on analyses of their language during the interview, psychiatrists presented LAI therapy in a negative light. Supporting this, 11 of 33 recommendations (33%) were accepted during the discussion, whereas in the postvisit interview, 27 of 28 patients (96%) who seemed to decline the initial recommendation said they actually would be willing to try LAI treatment.
CONCLUSIONS: These data support a preliminary hypothesis that the relatively low use of injectable antipsychotic therapies in the United States relative to other parts of the world is not fully attributable to patient rejection of the injectable modality. Rather, psychiatrists' ambivalence regarding the value of LAIs may play a significant role in the perceived difficulty with patient acceptance of this recommendation. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25939027     DOI: 10.4088/JCP.13m08946

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

2.  Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2.

Authors:  Martha Sajatovic; Ruth Ross; Susan N Legacy; Matthew Byerly; John M Kane; Faith DiBiasi; Heather Fitzgerald; Christoph U Correll
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-08       Impact factor: 2.570

3.  Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1.

Authors:  Martha Sajatovic; Ruth Ross; Susan N Legacy; Christoph U Correll; John M Kane; Faith DiBiasi; Heather Fitzgerald; Matthew Byerly
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-08       Impact factor: 2.570

4.  Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.

Authors:  Martin Lambert; Pedro Sanchez; Paul Bergmans; Srihari Gopal; Maju Mathews; Annette Wooller; Katalin Pungor
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-23       Impact factor: 2.570

Review 5.  Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.

Authors:  John M Kane; Joseph P McEvoy; Christoph U Correll; Pierre-Michel Llorca
Journal:  CNS Drugs       Date:  2021-10-11       Impact factor: 5.749

6.  Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study.

Authors:  Donica Janzen; Reece Ramkissoon; James M Bolton; Christine Leong; I Fan Kuo; Silvia Alessi-Severini
Journal:  Drugs Real World Outcomes       Date:  2022-05-16

7.  Perceptions and knowledge of antipsychotics among mental health professionals and patients.

Authors:  Lindah Cahling; Anders Berntsson; Gabriella Bröms; Lars Öhrmalm
Journal:  BJPsych Bull       Date:  2017-10

8.  Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians.

Authors:  Leslie Citrome; Emily Belcher; Sylvie Stacy; Mark Suett; Marko Mychaskiw; Gregory D Salinas
Journal:  Neuropsychiatr Dis Treat       Date:  2022-01-26       Impact factor: 2.570

9.  Drug-naïve first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China.

Authors:  Mengran Zhu; Maria Ferrara; Wenjian Tan; Xingbo Shang; Sumaiyah Syed; Li Zhang; Qilin Qin; Xinran Hu; Robert Rohrbaugh; Vinod H Srihari; Zhening Liu
Journal:  Early Interv Psychiatry       Date:  2020-09-14       Impact factor: 2.732

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.